The Search for Biomarkers of Alzheimer's Disease in Down Syndrome.

Handen (2020) maps where the field stands on Alzheimer’s biomarkers in adults with Down syndrome. The paper is a narrative review, not a new experiment. It also announces an ongoing longitudinal study that may soon give us hard numbers.

The review finds that most adults with Down syndrome will show Alzheimer’s changes by their late 60s. No single biomarker is ready for clinic use yet, but several are in the pipeline.

Allen et al. (2001) and Mansell et al. (2002) already showed that memory slips and pragmatic language drops can flag early dementia in the same group. Handen (2020) extends those behavioral clues by looking under the hood—at blood and brain signals.

Peters et al. (2013) proved you can safely run intrusive PET scans in adults with Down syndrome when you add extra consent checks. Handen (2020) leans on that proof to argue large biomarker studies are now feasible.

Haydar (2020) says we should spread therapies across the lifespan because Down syndrome brain changes are patchy and timed differently. Handen (2020) agrees early detection will be key to time those multi-modal interventions.

If you serve adults with Down syndrome, start prepping now. Track subtle losses in conversation or memory today; tomorrow you may add plasma or PET markers to your baseline. When the promised longitudinal data drop, you will be ready to plug the new biomarkers into your assessment plan and catch Alzheimer’s years earlier.